Mortality in diabetes: pancreas transplantation is associated with significant survival benefit

Pancreas transplantation in complicated type 1 (insulin dependent) diabetes mellitus improves the quality of life, increases longevity and stabilizes diabetic complications. There may be clinician reticence due to perceived poor outcomes with published associated mortality rates of 58 due to significant co-morbidities, particularly cardiovascular impairment. Retrospective analysis was performed on patients undergoing pancreas transplantation in a single centre since the programmes initiation [simultaneous pancreas kidney (SPK) 148, pancreas after kidney (PAK) 33 and pancreas transplant alone (PTA) 11] compared with a control group accepted contemporaneously onto the waiting list. The primary endpoint was patient mortality. The risk factors including medical and diabetic history, demographics, transplant type and waiting time were analysed. The waiting list mortality was 30 (35 of 120) compared with a mortality of 9 (20 of 193) post-transplantation (P 0.001). Deaths on the waiting list compared with transplantation up to 1 year had a relative risk of 2.67 (95 CI: 0.813.51; P 0.19), whilst those surviving 1 year had a relative risk of 5.89 of dying on the waiting list (95 CI: 1.703.20; P 0.0005). There were no differences in terms of cardiovascular or renal-associated risk factors, nor in other potential confounding factors other than duration of diabetes (P 0.02). Median survival from listing was shorter in younger patients (50; P 0.0001). Type 1 diabetics with renal failure listed for pancreas transplantation are at a significant risk of mortality even without surgery. Transplantation offers considerable survival benefits, despite associated surgical and immunosuppressive risks. In selected patients, pancreas transplantation remains the benchmark treatment for type 1 diabetes mellitus.